pracinostat + itraconazole

**Pracinostat + itraconazole** is an experimental drug combination comprising pracinostat, a histone deacetylase (HDAC) inhibitor, and itraconazole, a triazole antifungal agent. Pracinostat exerts antineoplastic activity by inhibiting HDAC enzymes, leading to increased acetylation of histone and non-histone proteins, promoting cell cycle arrest, and apoptosis in malignant cells. Itraconazole inhibits fungal cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, disrupting ergosterol synthesis and altering cell membrane permeability; it also has off-target effects such as inhibition of the Hedgehog signaling pathway and angiogenesis. This combination is not a standard or widely reported therapy, and there is currently no substantial published data on their combined use in clinical trials or standard clinical practice.

Other names

pracinostat and itraconazole combination